An interventional study of Risk assessment and Management Programme - Knee Osteoarthritis in Knee Osteoarthritis, sponsored by Chinese University of Hong Kong. Completed at 1 site in Hong Kong. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Chinese University of Hong Kong · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Osteoarthritis, Knee by Chinese University of Hong Kong — 9 open to participants now, 10 under way, none of them phase 3. Osteoarthritis, Knee · Chinese University of Hong Kong.
Among the 20 studies in Osteoarthritis, Knee by Chinese University of Hong Kong, this one is the 2nd largest by enrollment of the 16 interventional ones that give a count, is one of 4 that started in 2024, is one of 15 with no phase, and was the 17th registered.
3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.
Browse Osteoarthritis, Knee studies →9 of the 20 studies in Osteoarthritis, Knee by Chinese University of Hong Kong are open now, in 1 country. Recruiting first, the newest first:
Chinese University of Hong Kong · Sites in Hong Kong
Ages 50+
Chinese University of Hong Kong · Sites in Hong Kong
Ages 50–100
Chinese University of Hong Kong · Sites in Hong Kong
Ages 18+
Chinese University of Hong Kong · Sites in Hong Kong
Ages 50+ · Healthy volunteers
Chinese University of Hong Kong · Sites in Hong Kong
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 45 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 228 is above the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 64 across the 16 interventional studies, 85 across the 4 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Chinese University of Hong Kong is the lead sponsor of 1,458 studies on the registry; 478 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
2 of the studies in Osteoarthritis, Knee by Chinese University of Hong Kong that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06838663Chinese University of Hong KongRobotic-Assisted Total Knee Arthroplasty: Cruciate-Retaining Versus Bi-Cruciate Stabilized | 2027-06 |
| NCT07912333Chinese University of Hong KongWearable Device Guided Exercise for Patients on Total Knee Arthroplasty Wait-list | 2027-11-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies in Osteoarthritis, Knee by Chinese University of Hong Kong, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to determine the clinical effectiveness of a Chronic Care Model (CCM) named Risk Assessment and Management Program on Knee OA (RAMP-Knee OA) in adults with knee Osteoarthritis (Knee OA) at 52 weeks.
Participants will be screened for eligibility to participate. After confirming eligibility, participants will complete the baseline assessment and be randomized into one of the following groups (n=114 for each group):
Outcomes will be measured at baseline, week 16, week 32, and week 52.
The goal of this clinical trial is to determine the clinical effectiveness of a Chronic Care Model (CCM) named Risk Assessment and Management Program on Knee OA (RAMP-Knee OA) in adults with knee Osteoarthritis (Knee OA) at 52 weeks. RAMP-knee OA is designed based on the validated framework of CCM, which identifies six important components including self-management support, clinical information systems, delivery system redesign, decision support, health care organization, and community resources.
The main questions the study aims to answer are:
In comparison with people undergoing usual care, whether:
Participants will be screened for eligibility to participate. After confirming eligibility, participants will complete the baseline assessment and be randomized into one of the following groups (n=114 for each group):
Outcomes will be measured at baseline, week 16, week 32, and week 52. Demographic data and knee pain duration will be collected at baseline assessment. Outcomes to measure include the severity of knee pain, physical function, level of physical activity, self-efficacy, level of anxiety and depression, insomnia, loneliness, health-related quality of life, and lower limb muscle mass. The use of co-intervention, analgesics, and other over-the-counter drugs will be recorded.
The baseline characteristics of the two groups will be compared using the independent samples t-test or the Mann-Whitney test for continuous variables and chi-square test for categorical variables.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients allocated to the intervention group will continue their "usual care" at the GOPCs, plus enrolment into the RAMP-Knee OA program.
Behavioral: Risk assessment and Management Programme - Knee Osteoarthritis
Patients allocated to the usual care arm will continue receiving their "usual care" at the GOPCs without any additional intervention. "Usual care" typically refers to the established and commonly provided treatments, interventions, and practices that patients would receive in routine clinical practice for their particular condition or disease. For GOPCs in Hong Kong, the follow-up period for all chronic diseases is typically every 4 months. Each consultation at GOPC has an average duration of 3-5 minutes, during which physicians will address all chronic diseases, including knee OA. Physicians may provide brief healthcare advice, prescribe chronic medications and analgesics if necessary, and refer patients to physiotherapy if indicated. The management approach for knee OA and other chronic diseases will be solely at the discretion of the attending physicians.
(i) Arthritis education: Topics will cover the 21 key messages identified in International Consensus List of Essential Statements for Osteoarthritis "What Do People With Knee or Hip Osteoarthritis Need to Know" (ii) Structured land-based exercise: We have selected strengthening, flexibility training (stretching), and aerobic exercise as our key components because they are most applicable in primary care settings. (iii) Weight Management: Weight management will be offered for participants with a BMI ≥ 23 kg/m2. (iv) Counselling support for psychosocial health: counselling support will be provided for those with mild to moderate anxiety and depression, insomnia and loneliness identified in the risk assessment. (v) Dietary advice: Online dietary education for musculoskeletal health (with reference to local context) will be provided. The dietitian will also provide support regarding specific dietary advice on weight management.
Knee pain
Knee pain as measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Time frame: Baseline, week 16, week 32, week 52
Physical Function
Physical function measured by WOMAC function subscale
Time frame: Baseline, week 16, week 32, week 52
Physical function
Physical function measured by 30-second chair and stand performance test
Time frame: Baseline, week 16, week 32, week 52
Lower limb muscle mass
Lower limb muscle mass measured by bio-impedance analysis
Time frame: Baseline, week 16, week 32, week 52
Level of physical activity
Level of physical activity measured by Chinese International Physical Activity Questionnaire (Short form)
Time frame: Baseline, week 16, week 32, week 52
Self-Management efficacy
Self-management efficacy measure by Pain-Self Efficacy questionnaire
Time frame: Baseline, week 16, week 32, week 52
Level of Anxiety
Anxiety measured by Generalized Anxiety Disorder -7
Time frame: Baseline, week 16, week 32, week 52
Level of Depression
Depression measured by Patient Health Questionnaire -9
Time frame: Baseline, week 16, week 32, week 52
Insomnia
Insomnia measured by 7 item Insomnia Severity Index
Time frame: Baseline, week 16, week 32, week 52
Loneliness
Loneliness measured by 6 item De Jong Gierveld Loneliness Scale
Time frame: Baseline, week 16, week 32, week 52
Health related Quality of Life
Health related Quality of life measured by Euroquol- 5D-5L
Time frame: Baseline, week 16, week 32, week 52
Demographic data
Demographic data such as height, weight, BMI, age, sex, knee pain duration, chronic comorbid conditions, chronic medications
Time frame: Baseline
Plan to share: No
Ran from Apr 2024 to primary completion in May 2026, 25 months.
Of 1,114 non-industry interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's 25 months is above that.
Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: primary completion Nov 2025 → May 2026 and completion Apr 2026 → Jun 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chinese University of Hong Kong →